Interní Med. 2017; 19(3): 106-108 | DOI: 10.36290/int.2017.020

What has changed in treatment of patients with dyslipidemia?

MUDr. Ondřej Kyselák¹, prof. MUDr. Vladimír Soška, CSc.^{1, 2}

1Oddělení klinické biochemie, FN u sv. Anny v Brně, 2Biochemický ústav; Katedra laboratorních metod, Lékařská fakulta MU Brno

Summary: Dyslipidemia is very frequent metabolic disease in general population of developed countries. Last year, the European

Society of Cardiology (ESC) and European Society of Atherosclerosis (EAS) released new guidelines for management of dyslipidaemias.

In some groups of patients, the criteria for estimation of individual cardiovascular risk were changed.

Recommendations for target LDL cholesterol values were also modified and this is why reaching the target level of LDL cholesterol

should be now more difficult. Therefore, combination of hypolipidemic drugs and using new drugs (as PCSK9 inhibitors) will be needed.

Patient’s compliance to long-term treatment can be improved also by a new fixed combination of hypolipidemic drugs (“polypills”).

Keywords: cardiovascular diseases, ESC/EAS guidelines 2016, LDL cholesterol, statins, ezetimibe, PCSK9 inhibitors

Published: July 1, 2017  Show citation